Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda every six weeks
pembrolizumab · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Traditional approval of the alternative 400 mg every-six-weeks regimen across approved adult solid tumor indications.
LAMPGEN ANALYSIS
Why it matters
This converts the previously accelerated alternative schedule for solid tumor uses after FDA reviewed postmarketing data.
What research teams should watch
Keep dosing-schedule conversion distinct from indication conversions and document the chosen infusion interval.
PRIMARY RECORDS